Condition: Diabetic Pruritus · Efficacy of Pregabalin in Controlling Diabetic Pruritus Severity · Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh
Brief Summary: The goal of this randomized controlled study is to learn if pregabalin combined with emollients can reduce pruritus (itching) in people with Type 2 Diabetes Mellitus. The main questions it aims to answer are: Does pregabalin combined with emollients reduce pruritus severity compared to a placebo combined with emollients? What is the impact of pregabalin on the quality of life of participants suffering from diabetic pruritus? we will compare pregabalin plus emollient to a placebo plus emollient to see if pregabalin works better for reducing pruritus. Participants will: Receive either pregabalin 75 mg daily along with emollient therapy or a placebo along with emollient therapy. Visit the clinic at weeks 4, 8, and 12 for follow-up assessments, including: Pruritus severity using the Visual Analog Scale (VAS) and 5-D Itch Scale. Patient Global Impression of Change (PGIC) to measure overall improvement. This study will help determine if pregabalin, a drug used for neuropathic pain, can be an effective treatment for pruritus in people with diabetes.
This description comes directly from the study's public registry record.
KARTHIK N Dr, MBBS DNB General medicine · +91 9492115369 · nalam.karthik8788@gmail.com
Ashu Rastogi, DM Endocrinology · 9781001046 · ashuendo@gmail.com
Always discuss trial participation with your own doctor first.
| Department of Endocrinology , PGIMER, Chandigarh | Chandigarh, Chandigarh, India | Not Yet Recruiting |
| Department of Endocrinology , PGIMER, Chandigarh | Chandigarh, Chandigarh, India | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06790537